Skip to contentpdufa.bio

solriamfetol SUSTAIN

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

solriamfetol SUSTAIN is an Axsome Therapeutics, Inc. program in shift work disorder. Its next catalyst is a Readout in Q4 2027.

AXSM catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: shift work disorder. Sponsor: Axsome Therapeutics, Inc. (AXSM). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027AXSM

Specialist biotech funds holding AXSM, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
OrbiMed Advisors170,878$31.5 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is solriamfetol SUSTAIN's next FDA decision or readout?

The next tracked catalyst for solriamfetol SUSTAIN is a Readout in Q4 2027.

What happened at solriamfetol SUSTAIN's most recent FDA decision?

No FDA decision for solriamfetol SUSTAIN is in our archive yet.

What is solriamfetol SUSTAIN used for?

In our records solriamfetol SUSTAIN is under review or in development for shift work disorder.

Who makes solriamfetol SUSTAIN?

Axsome Therapeutics, Inc. (AXSM).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.